Investment Summary |
|
|---|---|
| Date | 2021-05-20 |
| Target | Swixx Biopharma |
| Sector | Distribution |
| Investor(s) |
HBM Partners AG
Merieux Equity Partners |
| Deal Type | Growth Capital |
SEARCH BY
Try For Free 7-Day Free Trial
| Category | Private Equity Firm |
|---|---|
| Founded | 2001 |
| PE ASSETS | 3.0B USD |
| Size | Mega |
| Type | Sector Focused |
HBM Partners is a private investment firm focused on investing in entrepreneurial biopharma and other healthcare-related companies in Europe, North America, India and other Emerging Markets. HBM looks to invest $5 to $50 million per transaction and will consider private and public companies. HBM Partners was established in 2001 and is headquartered in Zug, Switzerland.
| DEAL STATS | # |
|---|---|
| Overall | 56 of 65 |
| Sector (Distribution) | 1 of 1 |
| Type (Growth Capital) | 5 of 6 |
| Country (Switzerland) | 4 of 4 |
| Year (2021) | 11 of 16 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2021-05-05 |
APR
Balerna, Switzerland APR is a pharmaceutical company, identifying, developing, and commercializing known molecules engineered with drug delivery systems in niche and rare diseases on a global basis. The pipeline includes products at different stage of development concentrated in 3 selected therapeutic areas: inherited metabolic recessive diseases, cancer supportive care and skin rare diseases. APR was founded in 1990 and is based in Balerna, Switzerland. |
Sell | Fr.75M |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2021-06-18 |
Ambrx
San Diego, California, United States Ambrx is a clinical-stage biopharmaceutical company with a proprietary synthetic biology technology platform to design and develop next-generation antibody-drug conjugates (ADCs). The company is advancing a focused portfolio of clinical and preclinical programs designed to optimize efficacy and safety of its candidate therapeutics in multiple cancer indications, including ARX517, its proprietary ADC targeting PSMA for metastatic castration-resistant prostate cancer (mCRPC); ARX788, its proprietary ADC targeting human epidermal growth factor receptor 2 (HER2) for metastatic HER2+ breast cancer; and ARX305, its proprietary ADC targeting CD-70 for renal cell carcinoma. Ambrx was founded in 2003 and is based in San Diego, California. |
Sell | - |
| Category | Growth Capital Firm |
|---|---|
| Founded | 2009 |
| PE ASSETS | 1.3B EUR |
| Size | Large |
| Type | Sector Focused |
Mérieux Développement SAS is a venture and growth capital investment firm associated with family holding company Institut Mérieux. The Firm focuses on the health and nutrition sectors and will consider opportunities throughout North America and Europe. Mérieux Développement SAS was established in 2009 and is headquartered in Lyon, France.
| DEAL STATS | # |
|---|---|
| Overall | 15 of 20 |
| Sector (Distribution) | 1 of 1 |
| Type (Growth Capital) | 4 of 6 |
| Country (Switzerland) | 1 of 1 |
| Year (2021) | 2 of 4 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2021-01-28 |
Plantex
Saint-Michel-sur-Orge, France Plantex is a producer of botanical extracts. Plantex was founded in 1990 and is based in Saint-Michel-sur-Orge, France. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2021-07-02 |
DomusVi
Suresnes, France DomusVi is a provider of services to elderly people. It provides a full range of services to 42 000 residents and customers with 315 nursing homes, 16 residential facilities, 5 mental care facilities and 50 home care agencies throughout France, Spain and China. DomusVi was founded in 1983 and is based in Suresnes, France. |
Buy | - |
